Botanix Pharmaceuticals products
Novel Skin Delivery Technology
Delivering pharmaceuticals to the skin to treat disease is challenging. The skin’s role is to protect the body from a range of chemical and environmental assaults, so bypassing this active system requires an innovative approach. Botanix has exclusively licensed a novel transdermal drug delivery solution known as Permetrex™, which is designed to deliver pharmaceuticals through the skin more effectively. Right to where treatment is needed most.
Antimicrobial Pipeline
Antimicrobial Gel for Post Surgical Infections
BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). Botanix Pharmaceutical’s research to date shows synthetic cannabidiol rapidly kills MRSA within 10 minutes of exposure by a novel mechanism of action, and without allowing resistance to develop. BTX 1801 is initially focused on preventing surgical site infections (SSIs), which are caused by bacteria that get in through surgery incisions and threaten millions of lives every year. Botanix plans to test the capabilities of synthetic cannabinoid for fighting antibiotic resistance more broadly – a major global issue in healthcare – and to develop a novel platform product for multiple human and animal health applications.
Dermatology Pipeline
Program for Rosacea
BTX1702 is a new product opportunity for the treatment of papulopustular rosacea. Rosacea is a chronic inflammatory skin disease that often begins with a tendency to blush or flush more easily than other people, but can progress into many subtypes, including papulopustular rosacea. Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face, which affects more than 16 million Americans. The BTX1702 program is being expedited based on mechanistic data generated by Botanix that shows synthetic CBD exerts powerful anti-inflammatory and antimicrobial actions in skin – two key activities that are critical for successfully treating rosacea.
Transdermal Gel Formulation for Acne
BTX1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Acne is a skin condition that manifests in pimples, lumps and cysts and is the leading cause of visits to dermatologists and psychological difficulties in adolescents. It is the most common skin disorder in the US affecting 40-50 million Americans and it is estimated the market will grow to a value of US$5.9bn by 2025. Acne has multiple pathogenetic pathways including sebum overproduction, unwanted sebocyte proliferation, inflammation and bacterial infection. Synthetic CBD has been shown in scientific studies to normalise excessive lipid synthesis of human sebocytes, suppress cell proliferation, and provide an anti-inflammatory effect potentially reduce bacterial infection. In turn, this could help to reduce the occurrence or severity of serious acne.